A great few days connecting, learning & sharing insights in #HEOR and #MarketAccess.
Highlights from the team:
💡 Win – agility with AI
🔍 Sandra – real-world data in EAPs
🧠 Raymond – multi-agentic models
#SalutemInsights #TeamSalutem
A great few days connecting, learning & sharing insights in #HEOR and #MarketAccess.
Highlights from the team:
💡 Win – agility with AI
🔍 Sandra – real-world data in EAPs
🧠 Raymond – multi-agentic models
#SalutemInsights #TeamSalutem
⌛️HPR66 - Early Impact of the Mazars Review on Reimbursement Timelines in Ireland.
🕓 Tuesday 11th November - 16.00 - 19.00
#ISPOREurope #SalutemInsights
⌛️HPR66 - Early Impact of the Mazars Review on Reimbursement Timelines in Ireland.
🕓 Tuesday 11th November - 16.00 - 19.00
#ISPOREurope #SalutemInsights
#ISPOREurope #SalutemInisghts
#ISPOREurope #SalutemInisghts
Team Salutem presenting today:
🩺 EE702 – Economic Burden of Overweight & Obesity in Europe
💊 HTA52 – Barriers to Reimbursement in Ireland
📊 HPR43 – Managed Access Protocols in Ireland
🕥 10:30–13:30
Full details in images
#HEOR #MarketAccess #SalutemInsights
Team Salutem presenting today:
🩺 EE702 – Economic Burden of Overweight & Obesity in Europe
💊 HTA52 – Barriers to Reimbursement in Ireland
📊 HPR43 – Managed Access Protocols in Ireland
🕥 10:30–13:30
Full details in images
#HEOR #MarketAccess #SalutemInsights
We’re delighted to share that our team will be presenting multiple posters at ISPOR Europe 2025 in Glasgow this week.
Details on presentation times and locations to follow.
#ISPOREurope#SalutemInsights
We’re delighted to share that our team will be presenting multiple posters at ISPOR Europe 2025 in Glasgow this week.
Details on presentation times and locations to follow.
#ISPOREurope#SalutemInsights
Further details: www.linkedin.com/feed/update/...
Further details: www.linkedin.com/feed/update/...
From Germany to Canada, 14 market access experts (including Salutem Insights ) share HTA updates from Apr–Jun 2025.
📩 Want the full report? Email sandraredmond@saluteminsights.com
🔗 Sign up: bit.ly/AccessusHeal...
#HTA #SalutemInsights
From Germany to Canada, 14 market access experts (including Salutem Insights ) share HTA updates from Apr–Jun 2025.
📩 Want the full report? Email sandraredmond@saluteminsights.com
🔗 Sign up: bit.ly/AccessusHeal...
#HTA #SalutemInsights
Free to access now 👉 bit.ly/ValueinHealt...
Free to access now 👉 bit.ly/ValueinHealt...
🕐 12:20 BST
Register here :https://bit.ly/R-HTAWorkshop
#ISPOR #RforHTA #SalutemInsights
🕐 12:20 BST
Register here :https://bit.ly/R-HTAWorkshop
#ISPOR #RforHTA #SalutemInsights
Join Sandra Redmond from Salutem Insights tomorrow May 13th as she shares Ireland’s perspective on JCA alongside experts from Belgium, Luxemburg, Norway and Austria
🕓 16:00 | Free to attend
🔗 Register: bit.ly/3Z2iJiD
#EUHTA #HTA #MarketAccess #SalutemInsights
Join Sandra Redmond from Salutem Insights tomorrow May 13th as she shares Ireland’s perspective on JCA alongside experts from Belgium, Luxemburg, Norway and Austria
🕓 16:00 | Free to attend
🔗 Register: bit.ly/3Z2iJiD
#EUHTA #HTA #MarketAccess #SalutemInsights
Join Sandra Redmond from Salutem Insights on May 13th as she shares Ireland’s perspective on JCA alongside experts from Belgium, Luxemburg, Norway and Austria
🕓 16:00 | Free to attend
🔗 Register: bit.ly/3Z2iJiD
#EUHTA #HTA #MarketAccess #SalutemInsights
Join Sandra Redmond from Salutem Insights on May 13th as she shares Ireland’s perspective on JCA alongside experts from Belgium, Luxemburg, Norway and Austria
🕓 16:00 | Free to attend
🔗 Register: bit.ly/3Z2iJiD
#EUHTA #HTA #MarketAccess #SalutemInsights
🗓️ Sandra Redmond speaks on May 13 (Ireland focus).
🔗 Register: www.linkedin.com/feed/update/...
#EUHTA #HTA #MarketAccess #SalutemInsights
🗓️ Sandra Redmond speaks on May 13 (Ireland focus).
🔗 Register: www.linkedin.com/feed/update/...
#EUHTA #HTA #MarketAccess #SalutemInsights
40 drugs reimbursed in 🇮🇪 in 2024.
Avg. timeline: 580 days
⏱️ Faster, yes—but still nearly 2 years to access.
Progress is real, but high-need therapies can’t afford to wait.
#MarketAccess #HTA #Reimbursement #IrishHealthcare #SalutemInsights
40 drugs reimbursed in 🇮🇪 in 2024.
Avg. timeline: 580 days
⏱️ Faster, yes—but still nearly 2 years to access.
Progress is real, but high-need therapies can’t afford to wait.
#MarketAccess #HTA #Reimbursement #IrishHealthcare #SalutemInsights
The HSE Drugs Group is assessing more meds—but delays are growing.
⏳ Avg. 8 months to first meeting
📈 MAPs rising
🚪 Impacts access & strategy
See infographics for more detail👇
#MarketAccess #HTA #HSEDrugsGroup #SalutemInsights
The HSE Drugs Group is assessing more meds—but delays are growing.
⏳ Avg. 8 months to first meeting
📈 MAPs rising
🚪 Impacts access & strategy
See infographics for more detail👇
#MarketAccess #HTA #HSEDrugsGroup #SalutemInsights
Fast movers win! 🏁 1 in 6 HTA submissions in Ireland were made before EMA approval, speeding up reimbursement. Want to gain the advantage in Irish market access? See the data👇
#MarketAccess #HTA #Pharma #SalutemInsights #EUJCA #IrishHealthcare #HealthEconomics
Fast movers win! 🏁 1 in 6 HTA submissions in Ireland were made before EMA approval, speeding up reimbursement. Want to gain the advantage in Irish market access? See the data👇
#MarketAccess #HTA #Pharma #SalutemInsights #EUJCA #IrishHealthcare #HealthEconomics
The Rapid Review plays a key role in Irish reimbursement—how often does it lead to an HTA or price negotiations? ⏳ How quickly are they completed? 📊 What does this mean for 2025 market access? Swipe for insights! 🚀 #SalutemInsights #MarketAccess #HTA #Pharma
The Rapid Review plays a key role in Irish reimbursement—how often does it lead to an HTA or price negotiations? ⏳ How quickly are they completed? 📊 What does this mean for 2025 market access? Swipe for insights! 🚀 #SalutemInsights #MarketAccess #HTA #Pharma
At Salutem Insights, we track every medicine through the full Irish reimbursement process. What’s changing in 2024? 📉 Lower submission volumes, 📊 More complex HTAs, 🎗️ Oncology still leads.
For more insights: bit.ly/SILinkedIn
#SalutemInsights #MarketAccess #HTA
At Salutem Insights, we track every medicine through the full Irish reimbursement process. What’s changing in 2024? 📉 Lower submission volumes, 📊 More complex HTAs, 🎗️ Oncology still leads.
For more insights: bit.ly/SILinkedIn
#SalutemInsights #MarketAccess #HTA
priorities inlcuding faster access to medicines, increasing clinical trials, improving Irish competitiveness and a life sciences strategy. Fantastic to connect with other industry leaders!
#SalutemInsights #Pharma #IPHA
priorities inlcuding faster access to medicines, increasing clinical trials, improving Irish competitiveness and a life sciences strategy. Fantastic to connect with other industry leaders!
#SalutemInsights #Pharma #IPHA
#IPHAConference2025 #SalutemInsights
#IPHAConference2025 #SalutemInsights
Where are we now with Open-Source Models (OSMs) in Health Economics?
Our own Dr. Raymond Henderson & co-authors map the OSM landscape in this ISPOR Special Interest Group report.
📖 Read more: bit.ly/MappingtheLa...
#SalutemInsights #HealthEconomics #ISPOR #DataTransparency
Where are we now with Open-Source Models (OSMs) in Health Economics?
Our own Dr. Raymond Henderson & co-authors map the OSM landscape in this ISPOR Special Interest Group report.
📖 Read more: bit.ly/MappingtheLa...
#SalutemInsights #HealthEconomics #ISPOR #DataTransparency
#MarketAccess #HealthEconomics #HTA
#MarketAccess #HealthEconomics #HTA
Thanks to @thepmi.bsky.social for an informative session!
#SalutemInsights #PMI #Pharma #MarketAccess #USPolicy #EconomicImpact
Thanks to @thepmi.bsky.social for an informative session!
#SalutemInsights #PMI #Pharma #MarketAccess #USPolicy #EconomicImpact
The new JCA process is now mandatory for oncology drugs & ATMPs. Our MD, Sandra Redmond, attended the latest SANTE HTA webinar & shared key takeaways.
🔗 Read the full insights here: bit.ly/SalutemInsig...
#SalutemInsights
The new JCA process is now mandatory for oncology drugs & ATMPs. Our MD, Sandra Redmond, attended the latest SANTE HTA webinar & shared key takeaways.
🔗 Read the full insights here: bit.ly/SalutemInsig...
#SalutemInsights